S42 Vitamin D to prevent COVID-19 or other acute respiratory infections: phase 3 randomised controlled trial (CORONAVIT). (11th November 2022)

• Record Type: Journal Article
• Authors: Jolliffe, DA; Holt, H; Talaei, M; Sheikh, A; Griffiths, CJ; Shaheen, SO; Relton, C; Martineau, AR
• Is Part Of: Thorax. Volume 77(2022)Supplement 1
• Page Start: A29
• Page End: A29
• Publication Date: 2022-11-11
• Subjects: Chest -- Diseases -- Periodicals; Thorax; Chest -- Diseases; Periodicals; Periodicals; 617.54
• DOI: 10.1136/thorax-2022-BTSabstracts.48
• Languages: English
• ISSNs: 0040-6376

Abstract

Abstract : Introduction: Vitamin D deficiency associates with susceptibility to COVID-19 and other acute respiratory infections (ARI). Objective: To determine whether a 'test-and-treat' approach to vitamin D replacement in the general population reduces incidence of COVID-19 or other ARI. Methods: We randomly assigned 6200 UK adults to receive an offer of a postal vitamin D test with postal provision of a 6-month supply of higher-dose vitamin D (3200 IU/d, n=1550) or lower-dose vitamin D (800 IU/d, n=1550) to those with 25(OH)D <75 nmol/L vs no offer of vitamin D testing or supplementation (n=3100). The primary outcome was the proportion of participants experiencing at least one test- or doctor-confirmed ARI of any cause at 6 months. Secondary outcomes included incidence of COVID-19. Results: 2958/3100 adults randomised to intervention accepted the offer of testing, of whom 2690 (90.9%) had 25(OH)D <75 nmol/L and received vitamin D supplements (1356 higher-dose, 1334 lower-dose). 72 adults in the higher-dose offer group, 86 in the lower-dose offer group and 132 in the no offer group experienced at least one ARI of any cause during follow-up (odds ratio [OR] for higher-dose vs. no offer 1.05, 95% CI 0.78–1.40; OR for lower-dose vs. no offer 1.27, 0.96–1.68). COVID-19 was diagnosed in 32 adults in the higher-dose offer group, 48 in the lower-dose offer group and 68 in the no offer group (OR for higher-dose vs. no offer 0.90, 0.59–1.37; OR for lower-dose vs. no offer 1.37, 0.94–1.99). Conclusions: In adults with a high baseline prevalence of vitamin D insufficiency, a test-and-treat approach to vitamin D replacement did not reduce risk of all-cause ARI or COVID-19. Please refer to page A209 for declarations of interest related to this abstract.